PERSPECTA

News from every angle

← Back to headlines

JPMorgan Predicts Cancer Drug Stock Could Double

Investment bank JPMorgan has initiated coverage on a cancer drug stock with an overweight rating, projecting that its value could double as its treatment prepares to hit the market.

18 Aug, 16:37 — 18 Aug, 16:37
PostShare

Sources

Showing 1 of 1 sources
cnbcMostly Factual6d ago

This cancer drug stock could double as its treatment hits the market, JPMorgan says

The investment bank initiated coverage with an overweight rating.

Read full article →

Related Stories

Study Links Breakfast Timing to Lifespan

1h ago

Exploring Mental Health and Wellness Beyond Traditional Therapy, Including Sound Therapy

5h ago

Health Company Admits Maradona Test Mix-Up in Death Trial

5h ago

FDA Clears Roche and Eli Lilly's Alzheimer's Blood Test

7h ago